News
ANNX
4.700
+2.40%
0.110
Annexon, Inc.: Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Press release · 1d ago
Weekly Report: what happened at ANNX last week (0415-0419)?
Weekly Report · 6d ago
Annexon Insiders Land Bargain With Gains Of US$782k
Annexon, Inc. Insiders purchased US$1.01m worth of stock in the past year. The company has seen significant insider selling in the last three months. In the last year, Annexon insiders have sold US$99k worth of shares. But the company does have a high level of insider ownership. Annexon is owned by 1.2% of the company. The insider sale of Annexon stock is unlikely to be a cause for concern.
Simply Wall St · 04/17 12:00
TURNSTONE BIOLOGICS APPOINTS WILLIAM WADDILL TO ITS BOARD OF DIRECTORS
Reuters · 04/16 13:00
Weekly Report: what happened at ANNX last week (0408-0412)?
Weekly Report · 04/15 09:02
Buy Rating on Annexon Biosciences: Promising Pipeline and Strategic Growth Potential
TipRanks · 04/11 10:35
Annexon, Inc. (ANNX) Falls More Steeply Than Broader Market: What Investors Need to Know
NASDAQ · 04/10 22:15
Analysts’ Top Healthcare Picks: Alnylam Pharma (ALNY), ALX Oncology Holdings (ALXO)
TipRanks · 04/08 10:40
Weekly Report: what happened at ANNX last week (0401-0405)?
Weekly Report · 04/08 09:02
ANNEXON INC: ENTERED SALES AGREEMENT RELATING TO SALE OF SHARES OF COMMON STOCK, MAY OFFER SHARES OF COMMON STOCK, FROM TIME TO TIME, FOR $100 MLN
Reuters · 04/05 20:11
MGNX, SBNY and SLP are among after hour movers
On the Move MGNX, SBNY and SLP are among after hour movers. Signature Bank and Starbucks Corporation are among the losers. Cadiz and Kura Oncology are the biggest losers of the day. The market is down 1% in the last hour.
Seeking Alpha · 04/03 21:24
Cantor Fitzgerald Reiterates Overweight on Annexon
Benzinga · 04/03 13:33
Annexon: Unforced Error Sullies Prospects
Annexon, Inc. Is a clinical stage biotech company that is close to releasing topline data on its lead therapy, ANX005. It has the potential to become the first FDA approved therapy for Guillain-Barré syndrome (GBS) GBS is a rare disease that affects patients in different ways. Annexon is on the cusp of delivering top line data from its pivotal trial of its lead drug.
Seeking Alpha · 04/03 05:10
Annexon Is Maintained at Overweight by Wells Fargo
Dow Jones · 04/01 16:06
Annexon Price Target Maintained With a $12.00/Share by Wells Fargo
Dow Jones · 04/01 16:06
Wells Fargo Maintains Overweight on Annexon, Maintains $12 Price Target
Benzinga · 04/01 15:56
Annexon Price Target Raised to $13.00/Share From $11.00 by JP Morgan
Dow Jones · 04/01 14:04
Annexon Is Maintained at Overweight by JP Morgan
Dow Jones · 04/01 14:04
Wall Street Analysts Believe Annexon (ANNX) Could Rally 101.12%: Here's is How to Trade
NASDAQ · 04/01 13:55
Wells Fargo's high-conviction tactical longs and shorts for Q2
Wells Fargo's high-conviction tactical longs and shorts for Q2 include two Magnificent 7 names. The list includes 10 long (or Overweight) trades and 4 short (or Underweight) ideas. The Wells Fargo equity team identified 14 high- Conviction, catalyst-driven stock opportunities for the second quarter.
Seeking Alpha · 04/01 12:53
More
Webull provides a variety of real-time ANNX stock news. You can receive the latest news about Annexon, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About ANNX
Annexon, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in advancing a late-stage clinical platform of therapies for people living with classical complement-mediated neuroinflammatory diseases of the body, brain, and eye. Using its platform, it is identifying and characterizing the role of the complement pathway in three therapeutic areas: autoimmune, neurodegeneration and ophthalmology. Its lead candidate, ANX005, is an investigational monoclonal antibody (mAb), formulated for intravenous administration in a pivotal Phase III clinical trial for the treatment of patients with Guillain-Barre Syndrome (GBS). It is evaluating ANX007, an antigen-binding fragment (Fab), formulated for intravitreal administration, for the potential treatment of patients with geographic atrophy (GA). It is developing ANX1502, which is an oral small molecule for the treatment of autoimmune indications. It has developed ANX009, a C1q-blocking Fab formulated for subcutaneous delivery.